Glucar

Quick links to important sections

Glucar

Treatment option: Diabetes Mellitus

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glucar

Glucar is a prescription-only antidiabetic drug that belongs to the class of oral hypoglycemic agents. Its primary purpose is to help control high blood sugar levels that occur following meals, making it an adjunctive therapy alongside diet and exercise for managing Type 2 Diabetes Mellitus in adults.


Quick Facts

Property Description
Active ingredient Acarbose
Form Tablet (oral dosage form)
Pharmacological class Alpha-glucosidase inhibitor
Common use Glucose management (especially postprandial)
Origin Synthetic compound (pseudotetrasaccharide)

1. Glucar: Definition and Pharmacological Classification

The active ingredient in Glucar is Acarbose, a synthetic compound that is chemically defined as a pseudotetrasaccharide. Acarbose functions as an alpha-glucosidase inhibitor, which is a distinct pharmacological class clinically recognized for its utility in metabolic control. This classification is significant because, unlike many oral agents that increase insulin activity systemically, Acarbose acts locally within the gastrointestinal tract. Acarbose has been shown to lower glycosylated hemoglobin and blood glucose levels across various populations. This confirms that Glucar provides a means of achieving better overall long-term blood sugar control.

2. Composition, Form, and General Therapeutic Role

The medication Glucar is provided as a tablet, constituting a stable, oral dosage form. It is a single active ingredient product, combining the potent enzyme inhibitor Acarbose with various solid excipients required for the preparation. The therapeutic effect stems from the competitive, reversible inhibition of key intestinal enzymes, leading to delayed carbohydrate digestion. This mechanism acts to reduce the sharp peak in glucose concentration after consuming food. This indicates that Glucar is effective at mitigating the rapid surge in blood sugar known as the postprandial glucose spike, providing a crucial general benefit for managing metabolic stability, often used as the first step in dietary failure for Type 2 Diabetes management.

Regulatory References

  1. Acarbose - StatPearls - NCBI Bookshelf
  2. Acarbose: MedlinePlus Drug Information

What side effects are possible with Glucar?

Glucar, an alpha-glucosidase inhibitor, primarily targets carbohydrate digestion and is associated with a distinctive safety profile. The most frequently documented side effects are gastrointestinal disorders such as flatulence (very common), diarrhea, abdominal pain, and nausea/vomiting. These effects result from the drug's mechanism of slowing down carbohydrate breakdown in the intestine, leading to fermentation and gas formation.

Serious Adverse Reactions and Cautions

While generally not causing low blood sugar (hypoglycemia) when taken alone, the risk increases when Glucar is combined with other anti-diabetic agents like insulin or sulfonylureas. If hypoglycemia occurs, it must be treated with glucose (dextrose), not table sugar (sucrose), as Glucar impedes sucrose digestion.

Regulatory warnings emphasize the potential for serious liver injury. The drug is contraindicated in patients with cirrhosis and requires careful monitoring of liver enzyme levels in patients with pre-existing liver impairment. Allergic reactions, including severe rash and difficulty breathing, have also been reported and require immediate medical attention.

Restrictions and Special Populations

Glucar is formally contraindicated in patients with:

  • Diabetic ketoacidosis (DKA).
  • Chronic intestinal diseases or conditions where increased gas formation (e.g., in inflammatory bowel disease, colonic ulceration) is detrimental.
  • Known hypersensitivity to the drug or its components.

Due to insufficient data establishing safety, use during pregnancy and breast-feeding is not recommended. Caution is advised when prescribing Glucar to patients with severe renal impairment, as drug levels may increase significantly.

Overdose and Emergency Response

Glucar Overdose and when to seek help

The official regulatory profile for an overdose of Glucar is focused on localized gastrointestinal manifestations. The documented symptoms resulting from an acute overdosage include transient increases in flatulence, diarrhoea, and abdominal discomfort or pain. These effects are typically exacerbated when the overdose is taken alongside food or drinks containing carbohydrates.

A critical finding in the regulatory documents is that an overdose of Glucar tablets alone will not result in hypoglycemia (low blood sugar), distinguishing its overdose profile from many other systemic oral antidiabetic agents.

Seeking Urgent Medical Care

In all cases of suspected or confirmed overdose, regulatory guidance mandates that the individual seek immediate medical attention or contact emergency services immediately for clinical evaluation.

Mandated Management Procedures

Treatment of Glucar overdose is defined as symptomatic and supportive. No specific antidote is known. A unique, regulator-mandated intervention is required: the individual must specifically avoid food and drinks containing carbohydrates (such as polysaccharides, oligosaccharides, and disaccharides) for a period of four to six hours following the overdosage. Close clinical observation and the correction of fluid and electrolyte imbalances resulting from severe diarrhoea may be required during the monitoring period.

Therapeutic Uses of Glucar

Quick Facts: Glucar

  • Therapeutic Domain: Management of type 2 diabetes mellitus.
  • Primary Use: Supports the stabilization of blood glucose levels, particularly after meals.
  • Function: Utilized alongside a prescribed diet and exercise program.

What Glucar Treats: Main Uses and Benefits

Glucar is a therapeutic agent used for the management of type 2 diabetes mellitus in adults. It is part of a comprehensive treatment plan that includes appropriate dietary choices and regular physical activity.

The medication is indicated to assist in improving glycemic control, which refers to maintaining blood sugar levels within an established target range. A core therapeutic benefit of Glucar is its ability to help reduce the rise in blood sugar that commonly occurs following a meal. It may be prescribed as a monotherapy or may be utilized in combination with other oral anti-diabetic medications or insulin to support the overall management of the condition.

Through its use, Glucar contributes to the long-term objective of diabetes care: maintaining more stable blood glucose concentrations. This support of blood sugar stability is a component of a strategy to help mitigate the potential progression of complications associated with the chronic condition.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Glucar?

This section outlines official population eligibility and non-eligibility for Glucar, strictly based on authoritative regulatory documentation (such as FDA and EMA labeling).

Classification Status Rationale (As Per Official Labeling)
Severe Renal Impairment Contraindicated eGFR below 30 mL/ min/1.73 m^2 or End-Stage Renal Disease.
Metabolic Acidosis Contraindicated Any form of acute or chronic metabolic acidosis, including Diabetic Ketoacidosis (DKA).
Hypersensitivity Contraindicated History of serious reaction to the active substances or excipients.
Hepatic Impairment Not Recommended Use should be avoided due to increased risk of adverse events.
Pregnancy/Lactation Not Recommended Discontinue use upon detection of pregnancy (especially in 2nd/3rd trimester). Avoid while breastfeeding.

Age-Related Eligibility: Glucar is indicated for Adults and Pediatric patients aged 10 years and older. Use in children under 10 years has not been established. Geriatric patients (65 years) require more frequent assessment of renal function.

Use Restriction: The medicine is not recommended for patients with Type 1 diabetes mellitus or for those with moderate renal impairment (eGFR below 45 mL/ min/1.73 m^2) for glycemic control.

What should I know about interactions with other medicines?

The official interaction profile for Glucar (Acarbose) is structured around its local action within the gastrointestinal tract and its effects on blood glucose management, as documented in government regulatory sources. Minimal systemic pharmacokinetic interactions are noted.

Pharmacodynamic Interactions

Agent Category Official Interaction Outcome
Other Anti-diabetic Agents (e.g., Insulin, Sulfonylureas, Metformin) Additive blood glucose lowering effect that increases the risk of hypoglycemia.
Hyperglycemia-Causing Agents (e.g., Glucocorticoids, Diuretics) These agents may counteract the glucose-lowering effect of Glucar.

Local Interference and Systemic Exposure

  • Intestinal Adsorbents and Digestive Enzyme Preparations: These products, including those containing carbohydrate-splitting enzymes, may reduce the glucose-lowering effect of Glucar and should not be taken concomitantly.
  • Sucrose (Cane Sugar): Ingestion of sucrose or sucrose-containing foods is officially noted to cause increased gastrointestinal side effects, such as abdominal discomfort and diarrhea.
  • Digoxin: Glucar may decrease the bioavailability of digoxin, potentially requiring a dose adjustment for digoxin. Monitoring of digoxin plasma levels is considered.
  • Oral Neomycin: Co-administration may lead to enhanced reductions of postprandial blood glucose and an increase in the frequency and severity of gastro-intestinal side effects.

This interaction structure emphasizes the importance of managing combined glucose-lowering effects and avoiding co-administration with products that interfere with Glucar’s local action.

Mechanism of Action

Glucar is an alpha-glucosidase inhibitor that acts locally within the digestive tract. The drug's primary function is to inhibit enzymes—predominantly alpha-glucosidase located on the brush border of the small intestine, and to a lesser extent, pancreatic alpha-amylase. It achieves this through a competitive inhibition interaction, binding to the active sites of these enzymes.

This binding action blocks the final enzymatic breakdown of complex carbohydrates and starches into simple, absorbable glucose molecules. The resulting mechanistic cascade directly impacts the rate and timing of glucose entry into the systemic circulation. By slowing the enzymatic release of glucose from food, the drug delays its passage from the intestinal lumen into the portal circulation. This physiological modulation influences the dynamics of circulating sugar concentrations, leading to a slower, more gradual change in the systemic sugar concentration following consumption of carbohydrates.

Dosage and Administration Information

Glucar is an oral medication defined by its strict administration schedule relative to food intake. The official route of administration is oral, with the active ingredient Acarbose supplied as tablets in strengths of 25 mg, 50 mg, and 100 mg. The fundamental principle of use requires the medication to be taken three times a day (t.i.d.), precisely at the start of each main meal (breakfast, lunch, and dinner). The tablet should be swallowed whole with a small amount of liquid or chewed with the first mouthful of food.

The standard adult regimen typically begins with a low starting dose of 25 mg taken three times daily. The dosing is subject to gradual adjustment over time, generally at intervals of four to eight weeks, based on patient tolerance and therapeutic response. The typical maintenance range is between 50 mg and 100 mg three times a day. Maximum dose recommendations may vary by region; some authorities restrict the maximum to 100 mg t.i.d. for patients over 60 kg, while others permit up to 200 mg t.i.d.

Glucar is intended for continuous, long-term treatment. For specific populations, the administration guidance is clear: no dosage modification is required for older adults, but the medication is not recommended for use in patients under 18 years of age. A procedural constraint dictates that if a dose is missed after a meal has been consumed, it must be skipped entirely and the next dose taken only at the beginning of the next main meal, without attempting to compensate in between.

Recent Clinical Evidence

Research evidence / Overview of Studies for Glucar

Evidence for Use in Managing Type 2 Diabetes Mellitus

The research exploring Glucar (Acarbose) primarily uses Randomized Controlled Trials (RCTs) and systematic reviews that combine the findings from multiple trials. These studies research examined adults with Type 2 Diabetes to evaluate changes in their blood sugar markers. The RCTs evaluated Glucar both as a single agent and when it was studied for use alongside other common anti-diabetic medications, such as metformin or insulin.

In these trials, researchers primarily monitored two key measures of systemic or functional imbalance. The first was Glycosylated Hemoglobin ( HbA 1c), which is a marker related to long-term blood sugar stability. The second was Postprandial Plasma Glucose (PPG), which captures the rise in blood sugar following a meal. Studies reported patterns observed in the data related to both HbA 1c and PPG values compared to the control groups. Studies report that observed changes in body weight for the participants were typically minimal or neutral. However, research also describes an important observation: a notable proportion of study participants reported outcomes related to physical discomfort involving the stomach and intestines (such as flatulence or diarrhea). This pattern was observed in some studies with a higher rate of discontinuation compared to controls.

Evidence for Delaying Progression to Type 2 Diabetes

Glucar was evaluated in large-scale, long-term studies exploring its use in adults with Impaired Glucose Tolerance (IGT). IGT is a condition where blood sugar markers exceed normal ranges. These studies was studied for its role in the onset of T2DM itself.

Long-Term Data and Durability of Study Findings

Follow-up durations for many core regulatory trials for Glucar are typically intermediate. Studies exploring long-term symptom changes research examined outcomes such as long-term micro- and macrovascular complications. However, there is limited information for long-term outcomes beyond a few years, and long-term effects are not fully established based on the current body of core research.

What Research Gaps and Uncertainties Remain

Research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain. Comparative evidence is lacking regarding outcomes when Glucar is used instead of newer anti-diabetic agents for long-term complications. Findings were mixed regarding cardiovascular outcomes in the IGT prevention trials, reflecting that a definitive conclusion is not available in this area. Researchers suggest that more data are needed to fully characterize the long-term patterns across all potential patient groups.

Key Studies & References

  1. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data
  2. The effects of acarbose treatment on cardiovascular risk factors in impaired glucose tolerance and diabetic patients: a systematic review and dose–response meta-analysis of randomized clinical trials
  3. Acarbose - StatPearls - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Glucar (FAQ)

Q: How is Glucar different from other medicines that treat the same condition?

A: Glucar is unique because it belongs to a class of medicines that act locally within the digestive tract, rather than affecting insulin levels throughout the body. Official regulatory documents indicate its primary function is to slow the breakdown of carbohydrates in the intestine, which helps to manage blood sugar peaks after eating.

Q: How long does it usually take to notice any effects from Glucar?

A: The drug’s action begins immediately upon intake by slowing carbohydrate digestion. The official therapeutic response is generally evaluated over several weeks, with dosage adjustments typically considered at intervals of four to eight weeks based on blood sugar monitoring. This process allows the body time to adjust to the medication.

Q: Is it normal to feel a little dizzy when first taking Glucar?

A: Dizziness is not listed as a common side effect when Glucar is used alone. However, official product information states that dizziness can be a symptom of hypoglycemia (low blood sugar), which is a factor to consider when Glucar is taken in combination with other anti-diabetic medications like insulin or sulfonylureas.

Q: Are there any common side effects of Glucar that usually go away?

A: The most frequently reported side effects are gastrointestinal issues, such as flatulence (gas), diarrhea, and abdominal pain. Information derived from studies and regulatory data suggests these effects are often most noticeable when treatment begins, and they may lessen over the course of continued use for some patients.

Q: Should I worry about mixing Glucar with caffeine?

A: Official information indicates that substances which cause hyperglycemia (high blood sugar) may counteract the glucose-lowering effect of Glucar. Because caffeine can affect blood sugar levels, monitoring blood glucose levels is a factor to consider, particularly for patients with pre-existing cardiovascular conditions.

Q: If I feel better, is it okay to stop taking Glucar?

A: Glucar is intended for continuous, long-term management of Type 2 Diabetes Mellitus, which is a chronic condition. As Glucar is intended for continuous, long-term management of a chronic condition, a patient should seek professional guidance before making any changes to their treatment plan.

Q: Does Glucar affect how birth control pills work?

A: Official drug interaction data notes that some oral contraceptives (birth control pills) containing estrogen and progestin may interfere with blood glucose control. This interference may potentially reduce the effectiveness of Glucar. Monitoring blood sugar levels is a required consideration in this situation.

Q: How often do people need to have blood tests while on Glucar?

A: Official regulatory documents specify that monitoring of serum aminotransferase concentrations (liver function tests) occurs every three months during the first year of therapy and periodically thereafter. This assessment is necessary to monitor for potential serious liver injury.

Q: Why do some people need to take Glucar for a long time?

A: Glucar is prescribed for Type 2 Diabetes Mellitus, which is generally a chronic, progressive condition. It is used as an adjunct to diet and exercise to help maintain blood sugar control over the long term, rather than being a temporary treatment.

Q: Is Glucar a controlled substance or addictive in any way?

A: Official regulatory classification confirms that Glucar (Acarbose) is not designated as a controlled substance and is not considered to be addictive.

Q: What is the most common reason a doctor might discontinue Glucar treatment?

A: Clinical trial data summaries suggest that the most common reason patients stopped taking Glucar was due to the severity of the associated gastrointestinal side effects. These discomforts, primarily flatulence and diarrhea, were observed to be the factor most frequently linked to treatment discontinuation.

Q: Are there any known issues with taking Glucar while driving?

A: Glucar itself is not known to cause drowsiness. However, if the drug is taken with other medicines that can cause hypoglycemia (low blood sugar), symptoms like dizziness or weakness may occur, which may affect a person's ability to concentrate or perform tasks requiring alertness.

Q: Does Glucar have any black box warnings?

A: Official labeling documents, such as the FDA label, do not currently include a Black Box Warning for Glucar.

Q: Can Glucar be crushed or split if a person has trouble swallowing?

A: The official administration instructions state that the tablet should be taken with the first bite of the meal. It can be swallowed whole with liquid or chewed with the first mouthful of food, and the allowance to chew the tablet provides a method for administration that may be suitable for those with difficulty swallowing.

Q: How does Glucar affect my energy levels?

A: Glucar is not known to directly cause low energy or fatigue. However, if a patient experiences low blood sugar (hypoglycemia) from combination therapy, the associated symptoms, such as weakness or lethargy, could potentially affect energy levels.

Q: Does Glucar interact with alcohol consumption?

A: Official health monographs advise that alcohol consumption can impact blood glucose levels, leading to a risk of either high or low blood sugar in patients with diabetes. The use of alcohol with Glucar is a factor for consideration by a healthcare professional, particularly if blood sugar is not consistently controlled.

Q: Is it true that Glucar can cause sensitivity to the sun?

A: Photosensitivity (unusual sensitivity or reaction to the sun) is not listed among the common or reported side effects in the official product labeling for Glucar (Acarbose).

Q: What happens in the body when Glucar starts to wear off?

A: Glucar's effect is localized to the digestive tract and temporary, working only on the meal it is taken with. Once the carbohydrates from that meal have passed, the drug's effect diminishes, and the digestive enzymes resume their normal function until the next dose is taken with the next meal.

Q: What does 'contraindicated' mean in relation to Glucar?

A: The term 'contraindicated' is medical language used to mean that the medicine should absolutely not be taken. In the case of Glucar, official documents list conditions like liver cirrhosis or chronic intestinal disease where the risk of harm outweighs any potential benefit.

Q: Is Glucar a new or established drug?

A: Glucar (Acarbose) is considered an established medication. It was first approved by regulatory authorities for use in Type 2 Diabetes Mellitus in the mid-1990s, based on clinical research from that time.

Q: Is it okay to take Glucar if I have a history of heart problems?

A: Glucar is not specifically contraindicated for patients with a history of heart problems. However, regulatory documents caution that when used alongside other anti-diabetic medicines, the risk of low blood sugar (hypoglycemia) increases. This is a factor that requires careful management for patients with cardiovascular conditions.

Q: Are there specific foods or drinks to avoid while taking Glucar?

A: Yes. Official labeling specifically notes that ingestion of sucrose (table sugar or cane sugar) or foods containing it is associated with increased gastrointestinal side effects. Because of the drug’s mechanism of slowing carbohydrate digestion, consumption of large amounts of complex carbohydrates may also lead to increased GI discomfort.

Q: What should I do if I think I'm having an allergic reaction to Glucar?

A: Allergic reactions, though rare, have been reported and can include severe rash or difficulty breathing. Official guidance highlights the need for immediate medical attention if a serious allergic reaction is suspected. The severity of these reactions suggests that contacting emergency services or seeking immediate care in an emergency room is the appropriate action to consider.

How should Glucar be stored and disposed of?

How to Store and Dispose of Glucar (Acarbose)

Glucar (Acarbose) tablets require strict storage conditions to maintain their stability, as defined by regulatory labeling.


Storage Requirements

Glucar must be stored at room temperature, generally not above 25 C or 30 C. The product must be protected from light and moisture and should not be frozen or stored in areas of excess heat. Tablets should be kept in their original packaging or a tightly closed container.

It is mandatory to keep Glucar out of the sight and reach of children.


Disposal Instructions

Expired or unused Glucar must be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of the tablets via wastewater or typical household trash, unless specifically advised by a local take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glucar found in:

A-Z Index: